摘要
目的评估雷珠单抗与康柏西普治疗视网膜静脉阻塞性黄斑水肿的临床价值。方法选择2023年1月—2024年7月在江苏省兴化市人民医院眼科住院接受治疗的80例视网膜静脉阻塞(RVO)性黄斑水肿(ME)患者作为研究对象,将患者随机分为雷珠单抗组(n=40)和康柏西普组(n=40)。雷珠单抗组给予雷珠单抗玻璃体腔注射,康柏西普组给予康柏西普玻璃体腔注射。比较两组患者治疗前及治疗后最佳矫正视力水平(BCVA)、黄斑中心凹视网膜厚度(CMT)的改变情况;记录两组患者随访期间并发症(球内出血、高眼压、眼内感染)发生情况。结果治疗前,两组BCVA、CMT相比,差异无统计学意义(P>0.05);治疗后,随着时间的延长,BCVA增加、CMT减少。治疗1个月后,两组患者BCVA及CMT变化相比,差异无统计学意义(P>0.05);治疗6个月,康柏西普组BCVA高于雷珠单抗组,CMT低于雷珠单抗组(P<0.05)。两组患者随访期间并发症发生率相比差异无统计学意义(P>0.05)。结论康柏西普较雷珠单抗治疗视网膜静脉阻塞性黄斑水肿的远期疗效更佳,且两种药物均具有较好的安全性。
Objective To evaluate the clinical value of leizumab and Conbercept in the treatment of retinal vein obstructive macular edema.Methods January 2023 to July 2024,80 patients with RVOME who were hospitalized in the Ophthalmology department of Xinghua People's Hospital,Jiangsu Province were selected.Patients were assigned to leizumab group(n=40)or Conbercept group(n=40).Leizumab group was given intravitreal injection of leizumab,the Conbercept group was given intravitreal injection of Compacept.The BCVA and CMT were compared between the two groups before and after treatment.Record the occurrence of complications during the follow-up period of two groups.Results Prior to treatment,there was no statistically significant difference in Best Corrected Visual Acuity(BCVA)and Central Macular Thickness(CMT)between the two groups(P>0.05).Following treatment,BCVA showed an increase and CMT exhibited a decrease over time;however,after one month of treatment,no differences were observed in the changes of BCVA and CMT between the two groups(P>0.05).After six months of treatment,both BCVA and CMT in the Conbercept group were significantly higher than those in the Leizumab group,with CMT being notably lower than that of the Leizumab group(P<0.05).There was no difference in the incidence of Conbercept between the two groups(P>0.05).Conclusion The long-term efficacy of Conbercept is better than that of Leizumab in the treatment of retinal vein obstructive macular edema,and both drugs have better safety.
作者
陈海燕
CHEN Haiyan(Department of Ophthalmology,Xinghua People's Hospital Affiliated to Yangzhou University,Xinghua,Jiangsu 225700)
出处
《智慧健康》
2025年第15期102-104,108,共4页
Smart Healthcare
作者简介
陈海燕(1982-),女,汉族,江苏海安人,医学硕士,副主任医师,研究方向:眼科。
